More Accurate Imaging Is Not Stage Migration: Time To Move from "Hubble"to "Webb"in Hormone-sensitive Prostate Cancer

被引：6
作者：
Ayati, Narjess [1 ]
Herrmann, Ken [2 ,3 ]
Fanti, Stefano [4 ]
Murphy, Declan G. [5 ,6 ]
Hofman, Michael S. [1 ,6 ,7 ]
机构：
[1] Peter MacCallum Ctr, Prostate Canc Theranost & Imaging Ctr Excellence, Melbourne, Australia
[2] Univ Duisburg Essen, Dept Nucl Med, Essen, Germany
[3] Univ Hosp Essen, German Canc Consortium, Essen, Germany
[4] IRCCS Azienda Ospedaliero Univ Bologna, Nucl Med Unit, Bologna, Italy
[5] Peter MacCallum Canc Ctr, Dept Urol, Melbourne, Australia
[6] Univ Melbourne, Sir Peter MacCallum Dept Oncol, Melbourne, Australia
[7] Peter MacCallum Canc Ctr, Prostate Canc Theranost & Imaging Ctr Excellence, 305 Grattan St, Melbourne, Vic 3000, Australia
来源：
EUROPEAN UROLOGY | 2023年 / 83卷 / 01期
关键词：
D O I：
10.1016/j.eururo.2022.10.005
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：6 / 9
页数：4
相关论文
共 11 条
  • [1] Association of Bone Metastatic Burden With Survival Benefit From Prostate Radiotherapy in Patients With Newly Diagnosed Metastatic Prostate Cancer A Secondary Analysis of a Randomized Clinical Trial
    Ali, Adnan
    Hoyle, Alex
    Haran, Aine M.
    Brawley, Christopher D.
    Cook, Adrian
    Amos, Claire
    Calvert, Joanna
    Douis, Hassan
    Mason, Malcolm D.
    Dearnaley, David
    Attard, Gerhardt
    Gillessen, Silke
    Parmar, Mahesh K. B.
    Parker, Christopher C.
    Sydes, Matthew R.
    James, Nicholas D.
    Clarke, Noel W.
    [J]. JAMA ONCOLOGY, 2021, 7 (04) : 555 - 563
  • [2] PSMA PET for the Assessment of Metastatic Hormone-Sensitive Prostate Cancer Volume of Disease
    Barbato, Francesco
    Fendler, Wolfgang P.
    Rauscher, Isabel
    Herrmann, Ken
    Wetter, Axel
    Ferdinandus, Justin
    Seifert, Robert
    Nader, Michael
    Rahbar, Kambiz
    Hadaschik, Boris
    Eiber, Matthias
    Gafita, Andrei
    Weber, Manuel
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2021, 62 (12) : 1747 - 1750
  • [3] PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, 2 trial
    Buteau, James P.
    Martin, Andrew J.
    Emmett, Louise
    Iravani, Amir
    Sandhu, Shahneen
    Joshua, Anthony M.
    Francis, Roslyn J.
    Zhang, Alison Y.
    Scott, Andrew M.
    Lee, Sze-Ting
    Azad, Arun A.
    McJannett, Margaret M.
    Stockler, Martin R.
    Williams, Scott G.
    Davis, Ian
    Hofman, Michael S.
    [J]. LANCET ONCOLOGY, 2022, 23 (11) : 1389 - 1397
  • [4] Is Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Imaging Cost-effective in Prostate Cancer: An Analysis Informed by the proPSMA Trial
    Cardet, Rafael E. de Feria
    Hofman, Michael S.
    Segard, Tatiana
    Yim, Jackie
    Williams, Scott
    Francis, Roslyn J.
    Frydenberg, Mark
    Lawrentschuk, Nathan
    Murphy, Declan G.
    Lourenco, Richard De Abreu
    [J]. EUROPEAN UROLOGY, 2021, 79 (03) : 413 - 418
  • [5] New HST data and modeling reveal a massive planetesimal collision around Fomalhaut
    Gaspar, Andras
    Rieke, George H.
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2020, 117 (18) : 9712 - 9722
  • [6] Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study
    Hofman, Michael S.
    Lawrentschuk, Nathan
    Francis, Roslyn J.
    Tang, Colin
    Vela, Ian
    Thomas, Paul
    Rutherford, Natalie
    Martin, Jarad M.
    Frydenberg, Mark
    Shakher, Ramdave
    Wong, Lih-Ming
    Taubman, Kim
    Lee, Sze Ting
    Hsiao, Edward
    Roach, Paul
    Nottage, Michelle
    Kirkwood, Ian
    Hayne, Dickon
    Link, Emma
    Marusic, Petra
    Matera, Anetta
    Herschtal, Alan
    Iravani, Amir
    Hicks, Rodney J.
    Williams, Scott
    Murphy, Declan G.
    [J]. LANCET, 2020, 395 (10231) : 1208 - 1216
  • [7] Klaassen Z, 2022, LOW VOLUME CONVENTIO
  • [8] Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
    Parker, C.
    Castro, E.
    Fizazi, K.
    Heidenreich, A.
    Ost, P.
    Procopio, G.
    Tombal, B.
    Gillessen, S.
    [J]. ANNALS OF ONCOLOGY, 2020, 31 (09) : 1119 - 1134
  • [9] Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial
    Parker, Christopher C.
    James, Nicholas D.
    Brawley, Christopher D.
    Clarke, Noel W.
    Hoyle, Alex P.
    Ali, Adnan
    Ritchie, Alastair W. S.
    Attard, Gerhardt
    Chowdhury, Simon
    Cross, William
    Dearnaley, David P.
    Gillessen, Silke
    Gilson, Clare
    Jones, Robert J.
    Langley, Ruth E.
    Malik, Zafar I.
    Mason, Malcolm D.
    Matheson, David
    Millman, Robin
    Russell, J. Martin
    Thalmann, George N.
    Amos, Claire L.
    Alonzi, Roberto
    Bahl, Amit
    Birtle, Alison
    Din, Omar
    Douis, Hassan
    Eswar, Chinnamani
    Gale, Joanna
    Gannon, Melissa R.
    Jonnada, Sai
    Khaksar, Sara
    Lester, Jason F.
    O'Sullivan, Joe M.
    Parikh, Omi A.
    Pedley, Ian D.
    Pudney, Delia M.
    Sheehan, Denise J.
    Srihari, Narayanan Nair
    Tran, Anna T. H.
    Parmar, Mahesh K. B.
    Sydes, Matthew R.
    [J]. LANCET, 2018, 392 (10162) : 2353 - 2366
  • [10] Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
    Sweeney, Christopher J.
    Chen, Yu-Hui
    Carducci, Michael
    Liu, Glenn
    Jarrard, David F.
    Eisenberger, Mario
    Wong, Yu-Ning
    Hahn, Noah
    Kohli, Manish
    Cooney, Matthew M.
    Dreicer, Robert
    Vogelzang, Nicholas J.
    Picus, Joel
    Shevrin, Daniel
    Hussain, Maha
    Garcia, Jorge A.
    DiPaola, Robert S.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (08) : 737 - 746
12